Unasnemab

Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) -induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS) -induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments[1][2][3].